Department of Paediatric Haematology and Oncology, University Hospital Essen, Essen, Germany; Institute of Human Genetics, University Duisburg-Essen, Essen, Germany; Eye Oncogenetics Research Group, University Hospital Essen, Essen, Germany; German Consortium for Translational Cancer Research (DKTK), Partner Site Essen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Paediatric Haematology and Oncology, University Hospital Essen, Essen, Germany; Eye Oncogenetics Research Group, University Hospital Essen, Essen, Germany.
Eur J Cancer. 2020 Jul;133:47-55. doi: 10.1016/j.ejca.2020.04.005. Epub 2020 May 17.
Patients with heritable retinoblastoma are at risk for bilateral retinoblastoma and second primary malignancies (SPMs). The incidence of SPM is significantly raised after radiotherapy. We analysed the impact of the class of constitutional RB1 variant on the incidence of SPM in survivors with and without previous radiotherapy.
From 1940 to 2008, 655 national patients were treated for heritable retinoblastoma at the German referral centre. Data on SPM, therapy and constitutional RB1 variant were available for 317 patients (48.3%). Heterozygous RB1 variants were classified into variants with regular and incomplete penetrance for retinoblastoma.
SPM occurred in 51 of 317 survivors of heritable retinoblastoma. The incidence rate (IR) of SPM per 1000 person years was 8.4 (95% confidence interval (CI): 6.3-11.1) in individuals heterozygous for an oncogenic RB1 variant and 2.1 (95% CI: 0.0-11.4) with RB1 mosaicism. The incidence of SPM was higher in patients with regular penetrance compared with incomplete penetrance RB1 variants (IR 10.3 [95% CI: 7.5-13.8] vs. IR 3.2 [95% CI: 1.0-7.5]; p < 0.05). In the subgroup without previous radiotherapy SPM were only observed in patients with regular penetrance variants (IR 6.3 [95% CI: 3.0-11.5]). Carriers of incomplete penetrance variants developed similar tumour entities as those with regular penetrance.
Patients heterozygous for regular penetrance RB1 variants had a higher risk to develop SPM than patients with incomplete penetrance variants. Increased knowledge on genotype-phenotype relation regarding SPM may influence screening recommendations for SPM in survivors of heritable retinoblastoma.
遗传性视网膜母细胞瘤患者存在双眼视网膜母细胞瘤和第二原发性恶性肿瘤(SPM)的风险。放疗后 SPM 的发病率显著升高。我们分析了在有无既往放疗的幸存者中,RB1 种系变异的类别对 SPM 发生率的影响。
1940 年至 2008 年,德国转诊中心共治疗 655 例遗传性视网膜母细胞瘤患者。317 例(48.3%)幸存者的 SPM、治疗和种系 RB1 变异数据可用。杂合性 RB1 变异分为常发性和不完全穿透性视网膜母细胞瘤变异。
遗传性视网膜母细胞瘤幸存者中有 51 例发生 SPM。杂合致癌性 RB1 变异个体 SPM 的发病率(IR)为每 1000 人年 8.4(95%置信区间(CI):6.3-11.1),RB1 嵌合体为 2.1(95%CI:0.0-11.4)。常发性穿透性 RB1 变异与不完全穿透性 RB1 变异相比,SPM 的发生率更高(IR 10.3[95%CI:7.5-13.8]vs.IR 3.2[95%CI:1.0-7.5];p<0.05)。在无既往放疗的亚组中,仅在常发性穿透性变异个体中观察到 SPM(IR 6.3[95%CI:3.0-11.5])。不完全穿透性变异携带者发生的肿瘤实体与常发性穿透性变异相似。
常发性穿透性 RB1 变异的杂合子患者发生 SPM 的风险高于不完全穿透性变异患者。对 SPM 的基因型-表型关系有更多的了解,可能会影响遗传性视网膜母细胞瘤幸存者 SPM 的筛查建议。